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"It is the mark of the instructed mind to rest satisfied with
the degree of precision which the nature of the subject
permits and not to seek exactness where only an approxi-
mation of the truth is possible." (Aristotle) [1]
The modeling of a system involves finding a way to represent
the system so that it becomes more understandable. The major
aims of modeling are to provide elucidation, as well as informa-
tion on which to base clinical decisions. Unfortunately, we do
not always, as Aristotle has suggested, remain satisfied with the
degree of precision which the nature of the subject permits. The
tendency, in some modeling situations, has been to over
interpret the system. This results in more confusion than
elucidation which, in turn, acts as a deterrent to the more
widespread use of modeling procedures. On the other hand,
there can be, for a variety of reasons (such as bias, ignorance or
skepticism) a certain reluctance on the part of some physicians
to examine critically the potential patient benefits that modeling
can bring to an area such as renal replacement therapy. In this
article the potential advantages in applying simple models to
various forms of health care delivery are examined with particu-
lar reference to renal replacement therapy.
Kinetic modeling is based on a mathematical description of a
system, which permits analysis of the dynamics or the rate of
change of a system. In fact, it can be easily argued that unless
one understands the dynamics of a system, one's understanding
of that system is actually quite limited. To support this com-
ment the following examples of modeling applications are
examined: hemoperfusion uptake kinetics, heparin pharmacoki-
netics, urea kinetics, and mass transfer in peritoneal dialysis. In
addition, some suggestions are made for the use of a modeling
approach to examine the efficacy of plasmapheresis in the
treatment of autoimmune diseases.
Kinetics of hemoperfusion
Hemoperfusion has been used for a variety of clinical applica-
tions which has included hemodialysis and cases of liver failure.
However, its most widespread application has been the treat-
ment of acute drug intoxication. One benfit of applying kinetic
modeling to hemoperfusion treatment is that it can test the
likely outcome of a treatment change, or a given therapy, before
it is initiated. An appropriate example of this approach is given
by using kinetics to assess hemoperfusion for treating certain
types of drug overdose.
As will be illustrated in a later part of this review, most
models fall into the category of being diffusion limited, the rate
of mass transfer from one part of the body to another being
limited by transfer through the capillary membranes. In other
words, within any one compartment the time constant for
internal mixing is rapid compared to the time constant for
transferring out of that compartment; not all models follow this
pattern. In fact, in situations where significant partitioning
occurs, as in the case of a lipid soluble drug, a flow-limited
model is most applicable. In this situation, a drug may be
sequestered within adipose tissue such that its removal rate is
not dependent on its diffusion out of the compartment, but
rather on the rate of blood flow to that tissue. Perfusion of the
tissue would then be the dominating factor in the modeling of
such drug behavior.
Hemoperfusion (HP), provided the resin in the device does
not become saturated, is a much more efficient drug removal
mechanism than hemodialysis (HD). However, drug removal
with HP is still subject to the removal limitation of plasma
protein binding.
The questions as to the place of extracorporeal treatment in
acute poisonings or drug intoxication is quite controversial [2];
some groups are positive about the benefits [3, 4] while others
are decidedly more skeptical [5, 6]. We undertook the kinetic
modeling of drug removal by hemoperfusion, modifying a
previously developed flow-limited model of drug removal [7].
Drugs most commonly encountered in overdose situations
are psychotropic and these have varying degrees of lipid
solubility. The drugs selected by us for modeling and experi-
mental investigation were a highly lipid-soluble drug (glutethi-
mide) and a moderately lipid-soluble drug (pentobarbital).
These drugs currently are not particularly relevant from a
clinical viewpoint, however, they demonstrate the potential
usefulness of modeling applications to drug removal.
In vitro data were collected on (1) drug transfer rates into and
out of blood cells, (2) drug protein binding levels, and (3)
partition coefficients between surrogate human adipose tissue
(beef lard) and plasma. Using these data, a four-compartment,
flow-limited model consisting of blood, viscera, and lean and
adipose tissue was constructed and validated by comparison
with published glutethimide and pentobarbital data [8.1. The
computer simulation of drug behavior involved the solution of
the kinetic model on a digital computer using conventional
numerical solution procedures (4th-order Runge-Kutta).
Evidence of extracorporeal treatment efficacy for drug re-
moval has been variously based on the following observations:
(1) shortening of drug plasma half-life during treatment, (2) high
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device clearances, or (3) estimations of drug removal based on
device clearance and mean plasma levels during treatment.
However, because of metabolic clearance (which operates
continuously) and post-treatment rebound, such evidence can
be grossly misleading.
The model was therefore used to predict the time-course of
drug levels within the body following what would be considered
dangerously high ingestions of the drugs (10 g of glutethimide
and 3 g of pentobarbital). A time lapse of 26 hr was chosen
between drug ingestion and treatment initiation. Although this
figure may seem high and is based upon data published in the
early l960s, a shorter delay period (for example, 12 hr) would
not drastically alter the results obtained nor the arguments
based thereupon.
After a delay of 26 hr, hemoperfusion was simulated for a
duration of 6 hr. Treatment was followed by a recovery period
of 28 hr, during which time both rebound and endogenous
clearances were considered, so that a realistic assessment of
drug removal could be made. In a real-life situation, the
recovery period following treatment can extend over several
days. During that period the amount of drug metabolized (a
function of visceral concentration) is lowered because of the
concentration fall resulting from treatment. Failure to allow for
this effect results in an overestimation of treatment efficiency.
According to the model, at the time of treatment initiation,
41% of the pentobarbital and 48% of the glutethimide ingested
had already been metabolized, leaving only a little over half the
ingested amounts still in the body. Furthermore, over the 60 hr
following drug ingestion, 90% of the drugs would be metabo-
lized without extracorporeal intervention [2]. Simulation there-
fore suggests that the net amounts of drug removed by extracor-
poreal treatment are quite small.
Two points need to be made regarding this computer simula-
tion of drug overdose and extracorporeal removal. First, not all
drugs will behave similarly; it may well be that the lowering of
levels in the visceral circulation for some drugs may decrease
toxicity to a vital organ. Second, it should also be noted that
immediate removal of a poison cannot reverse the secondary
complications already due to the overdose, such as pneumonia,
respiratory failure, hypothermia, hypotension, and so forth. On
balance, the data obtained from the model used in this study,
supported by a number of clinical reports [2, 8] suggest that
intelligent, conservative therapy is the most rational course of
treatment for any poisoning resulting from drugs displaying
pharmacokinetic characteristics similar to those described here.
Heparin pharmacokinetics
The modeling of heparin behavior within the body is a rather
good example of the benefit of the kinetic modeling approach to
drug delivery. About 10 years ago it was shown that heparin
removal in the body is first-order [9]. This observation was used
by Gotch and Keen [10] to develop a model for minimal dose
heparinization. The model was later applied to anticoagulation
in routine hemodialysis [11] and subsequently to patients who
required heparin following a myocardial infarction [12].
Heparin modeling is based on the measurement of dose-
response characteristics. The extent to which heparin prolongs
clotting time can be assessed in a number of ways, but we prefer
the use of whole blood activated partial thromboplastin times
(WBPTT), which is based on a reagent (Optimised Activated
Thrombofax, Ortho Diagnostics, Raritan, New Jersey). The
WBPTT is linear with Lee-White clotting times, well past the
range normally experienced in dialysis procedures [10]; however,
WBPTTs are much shorter than Lee-Whites and are typically
within the range of 60 to 160 sec. It was therefore feasible to
develop a kinetic model for continuous heparinization, during a
3- to 5-hr dialysis, based on patient response to heparin as
determined by WBPTT measurements. (WBPTT measurements
require only a small amount of blood (0.4 ml) and reagent (0.2
ml) and, if carefully done, are accurate and reproducible [13].)
The first-order pharmacokinetic model depends on two pa-
rameters: patient sensitivity (S) to heparin and the first-order
elimination rate constant (K). These parameters form the basis
for individualized heparin therapy.
The effect of heparin on the clotting mechanism is virtually
instantaneous. When a bolus of heparin is given intravenously,
it is well mixed in the circulating plasma volume within 3 mm.
The magnitude of WBPTT prolongation [response (R), see] is
related linearly to the dose of heparin (D units) distributed in the
circulating plasma volume where
R = WBPTT — BL
and R = (S)(D). (1)
BL is baseline WBPTT without heparin administration and S
is defined as the sensitivity parameter. Correlation coefficients
of virtually 1 were obtained in every case when response was
plotted against dose [101. A single, well-controlled sensitivity
measurement is normally adequate to gauge dose response.
The equation for the first-order elimination of heparin during
continuous infusion is
d(VC) = — kC (2)
where V is distribution volume, C is plasma concentration, 'R is
constant infusion rate, and k is clearance.
The heparin clearance for dialysis patients is almost wholly
by nonrenal routes, since clearances by either the dialyzer or
the small amount of residual function of the remaining nephrons
is very small. On the assumption that heparin is distributed
within the plasma volume (Vu), the amount of circulating
heparin (Me) at any time is M = Equation (2) becomes
IRKMt (3)
where K (= k/Vp) is the elimination rate constant. For small net
changes in plasma volume, K can be assumed constant and
equation (3) is integrated to give
M = M0 exp(—Kt) + (1 — exp(—Kt) (4)
or from equation (1) where M is equivalent to D:
R1 = R0 exp(—Kt) + (1 — exp(—Kt). (5)
For a patient undergoing continuous anticoagulation, a de-
sired value of WBPTT (that is, the desired coagulation time, for
example, 125 see) is chosen. The required loading dose to
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achieve this level of anticoagulation is calculated from equation
(1) using the patient's measured sensitivity and the desired
response (Rd = WBPTT chosen minus base line value). The
infusion rate necessary to maintain R constant at Rd follows
from equation (5):
RdKIR----.
Thus, for precise anticoagulation, it is necessary to know only
the patient's S and the elimination rate constant, K.
Up to this time we have successfully modeled in excess of 200
dialysis patients for their heparin requirements. Mean loading
dose is 1700 500 U in the range 500 to 4000 U, while mean
infusion rate is 1500 300 U/hr, in the range 600 to 3000 U/hr.
In initiating modeling we start with a 2000-U loading dose and
continuous infusion at 1500 U/hr. S and K values are then
obtained and used for a better estimate of D and 'Rfor the next
dialysis.
For modeling to work properly, care must be taken to avoid
artifacts. These could be due to outdated Thrombofax, tem-
perature variations, the types of blood container used, and so
forth [13].
Recently, we examined whether or not heparin modeling was
able to control activation of the clotting and fibrinolytic systems
during dialysis (Flicker, Milthorpe, Schindhelm, McPherson,
Farrell, unpublished observations). Six patients were modeled
for their heparin requirements as shown in Table 1. They were
then monitored during dialysis for evidence of clotting and
fibrinolysis, by serial measurements of fibrinogen, antithrombin
III, plasminogen, and fibrin degradation products. Platelet
counts were also done. In contrast to other investigators, who
did not individualize heparin requirements, we found no activa-
tion of either the coagulation or fibrinolytic systems (Flicker,
Milthorpe, Schindhelm, McPherson, Farrell, unpublished ob-
servations). In addition, there was no evidence of thrombocy-
topenia. These data indicate the effectiveness of heparin model-
ing in hemodialysis both to maintain effective anticoagulation,
as well as minimize the risks associated with excessive
heparinization.
We have also extended heparin modeling to cardiac patients
maintained on continuous heparinization following myocardial
infarction [12], There would appear to be no reason why
heparin kinetic modeling cannot be extended to other medical
or surgical procedures requiring continuous heparinization.
Kinetic modeling of renal replacement therapy
From the clinical engineering viewpoint, modeling involves
selecting certain parameters as dependent variables which, in
the chronic uremia situation, are dialysis-dependent uremic
abnormalities; while the dialysis treatment regimen, coupled
with extradialytic acquisition and/or removal of uremic metabo-
lites, constitute independent variables.
The choice of dependent variables might encompass degree
of anemia, bone disease, abnormal carbohydrate metabolism,
mental alertness, correction of acid-base disturbances, levels of
lipids in the blood and so forth. The independent variables are
based on patient-hemodialyzer interactions. Certain variables
are easily defined and measured. These are: (1) dialyzer clear-
ance characteristics [for the solute(s) being examined]; (2)
length of dialysis; (3) frequency of dialysis; (4) dialysate bath
composition; (5) residual renal function; (6) extrarenal solute
removal mechanisms; (7) solute generation rates (dietary intake
or endogenous metabolism); (8) solute distribution volume; and
(9) intrabody mass transfer rates, if solute distribution is
(6) multicompartmental.
The interpretation of modeling data can be difficult, however.
Perhaps the greatest drawback in the assessment of even
carefully controlled studies is that many important uremic
abnormalities are likely to be multifactorial in nature and only
partially dependent on solute(s) concentrations. However,
carefully conducted crossover studies provide the only rational
basis for therapy evaluation. Even when initial assumptions for
doing a particular study are in question, if the study is carefully
done, clinical observations may be made which could result in
improved well-being for all maintenance dialysis patients. Nev-
ertheless, due to the complexity and multifactorial nature of the
uremic syndrome, all cause-effect relations, deduced from
particular modeling studies, must be viewed with a certain
degree of skepticism.
At the present time, the choice of treatment schedules for
dialysis patients at most renal units is quite arbitrary. Treatment
schedules and regimens are based primarily on the intuitive feel
of the physician, often with little regard to possible differences
between individual patients. Since blood flow rates, solute
generation rates, intrabody mass transfer rates, and so on, vary
considerably both within and between patients, a wide variation
in treatment times would be expected if patients were individ-
ually modeled. Yet most renal physicians are likely to be
skeptical of modeling. However, the choice of dialysis regimens
by intuition is far from satisfactory and dialysis-dependent
uremic lesions stand a greater chance for clarification through
kinetic modeling.
The application of modeling to renal replacement therapy is
not a new concept; Bell, Curtis, and Babb [14] over 16 years
ago, developed a simulation to describe patient/hemodialzyer
interactions. It was not, however, until the mid-l970s, that
kinetic modeling was directly applied in a fundamental way to
patient care by Gotch et al [15]. Nevertheless, a substantial
amount of indirect application of modeling concepts to endstage
renal disease emanated from innovative studies done in Seattle
during the early 1970s [16]. These modeling concepts hypothe-
sized that uremic toxins might be intermediate molecular weight
metabolites (middle molecules), having molecular weights
above 300, but below 2000 daltons. Work from the Seattle group
induced many clinical investigators to adopt various dialysis
strategies to elucidate the potential importance of so-called
"middle molecules." Dialysis strategies involved crossover
studies of lowered dialysate flow rates, of large area dialyzers
for shorter times, and studies on more permeable dialyzers.
Unfortunately, none of the approaches to the programing or
altering of dialysis schedules resulted in any significant elucida-
tion of uremic toxicity. However, important modeling concepts
such as net metabolic production rates and residual renal
function were highlighted [17] and formed a basis for a more
logical application of modeling to dialysis therapy, including
urea kinetic modeling (UKM). This latter concept was pio-
neered by Gotch in the mid-l970s [18] on the premise that
although urea was not a toxin per se [19], it certainly could be
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Table 1. Heparin modeling of hemodialysis patients
used as a marker of protein catabolism [20] as well as an
indicator of general metabolite production.
The major premise behind the modeling of dialysis therapy is
that some of the signs and symptoms of the uremic syndrome
are linked to solute concentration-time profiles. With this
assumption it was logical to consider dialysis as negative drug
administration [21]. In other words, pharmacokinetic principles
should apply to dialysis therapy, but with a slightly different
emphasis: instead of solute (drug) being administered over
evenly spaced time periods, one removes solute (waste metabo-
lites) on a regular basis. With this pharmacokinetic approach,
urea kinetics have been applied with some success both to
select dialysis therapy regimens [15, 22, 23] and to assess
nutritional requirements of dialysis patients, both adult [24—27]
and pediatric [28]. A number of different approaches can be
taken in the modeling of patient-hemodialyzer interactions [29].
In the case of urea kinetics the mathematics are simple, the
application is productive and interest in the area is growing. For
these reasons the background of applying urea kinetics to
dialysis therapy is described in some detail in the next section.
Urea kinetic modeling
The use of urea modeling in dialysis is now widespread [30]
and its acceptance has been quite enthusiastic [28, 30—34]. The
conclusions from a number of recent studies, which describe
experiences in groups of up to 100 patients ranging over 2 to 3
years, is that UKM provides the following benefits: (1) It is an
effective method of prescribing the correct amount of dialysis
therapy [28]; (2) it is extremely cost effective [351; (3) it permits
excellent nutritional counseling and monitoring [28, 30—34]; (4)
it guards against over-vigorous or prolonged treatments, while
maintaining an adequacy of dialysis [28, 34]; (5) it provides
excellent quality control on the dialysis procedures allowing for
more technically proficient delivery of health care [34]. Since
UKM is the most widespread application of modeling and the
easiest to comprehend, it warrants more detailed discussion.
The basis of all solute kinetic modeling is the application of
material balance equations to the body. For each pool, the rate
of accumulation of a solute is given by the net difference
between solute addition to the pool (net generation or produc-
tion) and its removal or clearance. For a small molecule such as
urea, which distributes rapidly over body water [36] relative to
its dialytic removal, a single-pool model of the body suffices.
The mathematical description of the dialysis procedure is as
follows: The rate of metabolic accumulation equals net meta-
bolic production rate minus rate of removal or whole body
clearance
(VC)
= G (Kd + Kr) C (7)
where G refers to net production rate of metabolite.
For the off-dialysis period [for a patient with some remaining
renal function (Kr)] the expression is:
d(VC)
= G — KrC (8)
G =
—
(9)
where 8 refers to the interdialytic period.
Equation (9) is a useful expression for estimating a generation
rate which can then be used for further metabolic assessment.
For example, net urea generation rate can be used to assess
protein catabolic rate (PCR, g/24°) from the following expres-
sion [21, 37]:
PCR = 0.262 (G + 54) (10)
where G, in this case, has units of .rM/min.
An example is instructive. Assume that a 70-kg anuric patient
at the end of a dialysis treatment has a serum urea level of 12
mM/liter and, during the 44 hr before the next dialysis, puts on
1.5 kg of fluid. The patient begins the next dialysis with a urea
level of 29 mM/liter. From equation (9), assuming a urea
distribution volume of 58% of ideal body weight, the net urea
generation is:
= ix (0.58 x 70 + l.5)(29) — (0.58 x 70)(12)
= 278 ILM/min
(44)(60)
(Note that the increase in patient weight of 1.5 kg is considered
to be solely additional fluid).
From equation (JO) PCR is 87 g/24°, which equals dietary
protein intake (DPI) if the patient is in nitrogen balance. Based
on the patient's ideal weight, this computes to an acceptable
DPI of 1.2 g/kg124°. This rather trivial example indicates the
potential usefulness of urea kinetic modeling, in this case,
without the need for a computer.
This analysis can also be used with minor modification in
CAPD where it has been shown that there are no abnormalities
in nitrogen metabolism [37]. Equation (10) applies equally well
to CAPD except that to arrive at DPI, protein losses in the
Baseline
WBPTT S
Patient sec .sec/IU
Heparin
Heparin
loading
Heparin
infusion
t'/2 dose rate
mm iu lU/hrKhr
0.95 44 2000 19001 83 0.020
2 82 0.020 1.3 31 2000 2300
3 78 0.031 0.94 44 1300 1300
4 78 0.034 1.7 25 1300 2300
5 85 0.036 1.2 35 1000 1200
6 71 0.027 1.0 41 1800 1900
Mean + sn 80 5 0.028 0.007 1.2 0.3 37 8 1600 400 1800 500
On-dialysis
WBPTT range
Sec
120 to 140
115 to 140
120 to 140
110 to 130
110 to 120
115 to 140
110 to 140
(overall range)
dt
and for the anuric patient:
V2C2 — VC1 = G 0
or
0
(11)
KUf
K - Kf
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peritoneal dialysate (g/24°), must be added to PCR values. We
U) = v + t (15)derived the following DPI correlation for CAPD [37]. o
DPI = 0.301 (G + 52) (12) where W8 = 1000 (W — WId). (16)
Mean amino acid losses to the dialysate in CAPD are 3 0.8
g/24° or 0.48 g nitrogen per day [37]. These were neglected in
deriving equation (12). An argument could be made that this Expanding equation (8), substituting equation (15), separating
nitrogen loss should be taken into account. However, the error variables and integrating postdialysis urea from (CE!) to the next
in DPI calculation would only be 5%. Nevertheless, the predialysis urea concentration (C02), and rearranging the solu-
correlation would be improved by adding both amino nitrogen tion in terms of the generation rate, yields:
losses and normalizing the intercept value of 52 based on actual
patient weight. Kr
There are further simple applications of equation (8). For a G = + ) (C02 (1 + Wg/V) O/Wg + I) — C) (17)patient who is in steady state renal failure the left-hand side of (1 + + I) —
the equation is close to zero so that G = KrC = Q0C0. in other
words G equals urine flow rate (Q) times urine solute concen- Equations (14) and (17) can be simply solved iteratively for
tration (C0). Urine collections and urinalysis provide simple V0 and G on a digital computer. The only clinical data required
estimates of the generation rates of urea and creatinine and
are pre/post chemistries for one dialysis, followed by prechem-
these can be used for assessing patient nutritional and metabolic istries for the next. It is important, however, to control Qb, Qd
status. It is also obvious from equation (8) that variations in (and heparin dose) and to have accurate values for td, 0, K0f andgeneration rates can lead to gross changes in serum concentra-
Kd.tions of metabolites without any change in renal clearance. In The above equations can also be rearranged as required. For
contrast, serum concentrations may remain static, despite example, if dietary intake is known, the relationship describeddeteriorating renal function, if generation rates decrease for by equation (10) can be used to determine G which, when
whatever reason. In other words, without a knowledge of the
combined with equation (14), provides the dialysis time neededdynamics of a system, the system is incompletely understood, to give a predetermined predialysis serum urea concentration.Urea kinetic modeling (UKM) can also provide feedback on UKM has been used successfully to provide quality control
the quality of dialysis treatment. The basic approach to UKM is
on the delivery of dialysis therapy [21]. This process involvesto measure before pre- and postdialysis serum concentrations
comparing and contrasting expected dialyzer performance (Kd)
over a dialysis cycle. With a knowledge of dialyzer clearance, with estimated performance (KE). This can be done exactly on a
time on dialysis, off-dialysis period, and patient residual renal digital computer, or more inexactly using a hand calculator. Forfunction, net urea generation rate can be determined relatively example, if we ignore the extent of net solute production during
easily. In turn, this parameter can be used for both dietary a dialysis procedure and pre/post blood concentration measure-
counseling and to select a more appropriate dialysis schedule. ments are done, then clearance can be estimated as follows:This could involve changing both dialysis frequency and time,
although the latter is more likely to be altered.
Urea distribution volumes are known to vary considerably K = — In (c0\
td \Cf) (18)from patient to patient; it is better, therefore, to measure this
parameter rather than assume a fixed value of, say, 58% of body
weight. Although the programing and the mathematics of UKM (A previously determined value of the distribution volume is
are quite simple, and can be done on a reasonable calculator, it used). If K is significantly lower than the anticipated Kd based
is more convenient to use a digital computer. In addition, the on dialyzer operating conditions, then one might suspect:
computer can provide a data-base management system for easy clotting in the dialyzer (indicating the need for heparin model-
access to patient records. ing), fistula recirculation, or perhaps an abnormally low blood
It is useful at this stage to look at the solution to equations (7) flow rate.
and (8). Urea distribution volume as a function of time is given In summary, those renal units which have been exposed to
by: urea kinetic modeling have been almost universally impressed
by its efficacy. However, this positive experience with model-
V (t) = Vo — K0ft. (13) ing procedures could be viewed as the tip of quite a large
iceberg in terms of the potential for general modeling applica-Expansion of equation (7), substitution of equation U3), tions to health care delivery.
separation of variables, and integration from the predialysis
urea concentration (C01) to the immediate postdialysis urea Modeling in peritoneal dialysis (PD)
concentration (C1) for the dialysis period (td) gives: There has been relatively little published, to our knowledge,
Kftd regarding the use of modeling in PD. In terms of the massV0 =
. (14) transfer process occurring within the peritoneal cavity, there
— (K — KUf)CtI 1
________ have been recent reports [38—41] proposing methods for deter-— [G (K Kuc)c01j mining the maximum clearance or permeability of the peritone-
um. These approaches are useful, although a digital computer is
The unknowns in this expression are V0 and G. Kd, K0, and generally needed.
td are known for a particular dialyzer and dialysis regimen. Modeling of peritoneal mass transfer is based on the determi-
A volume relationship for the off-dialysis period is: nation of the overall mass transfer coefficient times effective
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m = KBD (Cb — Cd) + KfSCb
diffusive convective
where RB is the blood-film resistance, RD is the dialysate-film
resistance, and Rm is the membrane resistance. This parameter
should be independent of dialysis regimen and ultrafiltration
effects.
A possible model for peritoneal mass transfer rate (m, mM!
mm) is given by the sum of diffusive and convective mass
transfer:
membrane area (KBD) or the maximum clearance. KBD is recently suggested [44]. The approach is not as accurate as
directly related to the effective peritoneal membrane area (Am) computer-based modeling, but it will provide numbers which
and inversely related to overall resistance to solute flux as are sufficiently accurate for clinical purposes.
follows: If we return to equation (22) and assume that, first, the
sieving coefficient is unity and second, blood concentration of
KBD = Am (19) solute is constant then, since K1 equals dVd/dt, equation (22)
RB + Rm + RD reduces to:
d(CdVd)
—
d(CbVd)
dt KBD(Ch
— Cd) + dt (25)
or
dVd(Cb — Cd)
— —KBD (Vd(Cb — Cd)). (26)ut
(20) This expression may be integrated, after separation of varia-bles, to give
FVd(Cb — Cd)] dt
In L Vd1(Cb — Cd)]
= KBD J v—. (27)
The integral on the right hand side of equation (27) can be
obtained numerically or graphically. Alternatively, a mean
value of Vd' may suffice, if the time interval is sufficiently
short, for example, 15 mm. In other words, if the dwell time is
45 mm and samples (subscripts 1 and 2) of peritoneal dialysate
are taken every 15 mm, then three values for KBD would be
obtained where
______ ______
FVd(Cb — Cd)Il
KBD ln I. (28)(t2 — t1) LVd2(Cb — Cd)2 ]
where S is the solute sieving coefficient and b refers to mean
solute concentration within the peritoneal membrane. Under
the conditions of PD, Cb can be replaced by Cb without
significant error [41].
Urea and creatinine kinetics can be described by a single-pool
constant volume model for the patient and a variable-volume
dialysate pool, as follows:
d(CbVb)
= KBD(Cd — Cb) — KUfSCb + G — KrCb (21)
d(CdVd)
= KBD(Cb — Cd) + KSCb. (22)
The ultrafiltration rate can be approximately represented by Data in Table 2 from Canaud and Mion (Service de Nephrolo-
an exponential profile where: gie Hôpital and the University of Montpellier, Montpellier,
K = A e_at (23uf a / France) relate the peritoneal volumes and urea dialysate con-centration for a patient on CAPD. For this patient the serum
and urea concentration was constant at 16.7 mM/liter and volume
Vd = di + A (1 — e_at) (24) changes in the peritoneal cavity were estimated from an albu-mm marker, whose dilution was used as an indicator of ultrafil-
A and a are constants representing, respectively, the total tration. (The dialysate contained 4% dextrose and the albumin
amount of fluid ultrafiltered and the time constant for ultrafiltra- was labeled with Tc. Corrections were made for transfer of
tion. VdI is the initial volume of dialysis fluid, albumin from the dialysate to the patient.)
For larger molecular weight solutes, a two-pool model is Using equation (27) the following values of KBD are obtained
needed to describe the process, and the mathematics are a little for 15-mm intervals: 14.1, 14.3, 20.6, 18.3 to give a mean urea
more difficult [41]. However, these models are relatively easily KBD value of 17 3 mI/mm.
programmed on a digital computer and can be used to follow This equation can be easily programed on a small computer
changes in the permeability of the peritoneal membrane during or calculator. Since patients conventionally come to the clinic
long-term CAPD [421. This has been successfully done over a 2- to have their administration lines changed on a monthly basis, it
year period [43]. would be relatively easy to undertake KBD measurements there
It is also relatively simple to get nutritional feedback from every 2 to 3 months. In this way changes in the permeability of
patients on CAPD [37]. As with hemodialysis, net urea genera- the peritoneum could be monitored with relative ease. It is also
tion rate has to be determined. But this is a much simpler advisable to conduct metabolic assessment at the same time as
proposition with patients on CAPD, as opposed to HD or IPD, a clearance assessment is done. With a 24-hr dialysate and/or
since serum chemistries are essentially steady state. This means urine collection, urea generation rate can be determined easily
that the calculation of G for urea simply involves collection of and used to predict DPI [37]. With a suitably programed
dialysate and urine over a 24- to 30-hr period. We have followed microcomputer, data could be reduced and stored for future
PCR and DPI for CAPD patients over extended periods using reference; and it again can be done with relative ease.
this approach [37]. In summary, it would appear to be critically important to
A shorter route to obtaining information on maximum clear- kinetically monitor patients on a regular basis, not only to
ances or overall MTC times effective membrane area (KBD) was provide more efficacious treatment but also to assess metabolic
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Table 2. Peritoneal volumes and urea dialysate concentration for a
patient on CAPD
Cd
mM/liter
V
ml
0 1983 1.7
15 2304 5.0
30 2543 7.0
45 2938 9.2
60 3146 10.3
changes, particularly when there is a change in treatment
schedule or modality. By examining the dynamics of the
patient-treatment system, an in-depth appreciation of metabolic
adjustment is obtained. The physician then can decide if the
changes are acceptable or not and may elect to either change
the treatment completely or perhaps alter it in a way that would
not have been obvious, if kinetic modeling procedures were not
undertaken.
Modeling of membrane plasmapheresis
Plasma exchange has been used to treat an extremely broad
range of diseases, with probably the most striking success being
reported in the treatment of autoimmune diseases. In particular,
the treatment of antibody-mediated renal disease is highlighted
as the most singularly successful application of plasma ex-
change therapy {45].
For diseases which appear to result from abnormally high
levels of circulating substances of high molecular weight, the
use of plasma exchange seems obvious. The various offending
substances include antigens, antibodies, immune complexes
(ICs), complement components, fibrinogen, protein-bound tox-
ins, and perhaps a variety of other nonspecific inflammatory
mediators. These species possess molecular weights ranging
from as low as 69,000, in the case of toxins bound to albumin,
up to perhaps several million daltons for large immune com-
plexes. Plasma exchange provides an ideal method to reduce
the circulating levels of these large molecular weight species.
In theory, the potential applications of plasma exchange
therapy (PET) are limited only by one's imagination. It is,
however, an open question as to whether plasma exchange is an
entirely appropriate therapy to use in some of the disorders for
which it has been used. In fact, there has been a tendency, on
the part of some researchers, to apply various forms of extra-
corporeal treatment in areas in which they were hardly likely to
have any salutory effects even when based on a rather liberal
interpretation of efficacy. And it would appear that some of the
current claims for the efficacy of PET are based on anecdotal
data. Kinetic modeling of the treatment is likely to provide a
firmer basis on which to decide the value of the treatment.
Recently, the theoretical aspects of using plasmapheresis to
treat immune complex disease were discussed by Clough and
Calabrese [46]. The area is very complicated since it is often
unclear whether or not the removal of complexes per se is likely
to be efficacious. For example, if the complexes being removed
had an antibody excess they are likely to act as B-cell suppres-
sors so that IC removal may actually result in clinical deteriora-
tion. On the other hand, if the ICs have an antigen excess,
removal is likely to improve a patient's clinical status. Clearly,
a study of immunoglobulin, antigen or IC kinetics is not going to
be able to predict clinical efficacy; however, it will aid in the
quantitative evaluation of the therapy. A simple model to use in
this regard, if one ignores the possible effects of feedback on
antibody synthesis, is proposed below. It is assumed that the
species in question has a constant synthesis rate and is confined
during treatment time to the vascular space. The rate of
accumulation is then related to net synthesis and extracorporeal
removal as follows:
d(VC1) = p1 — (Q, + K1)C1 (29)
where subscript I refers to the immunoglobulin, antigen or ICs,
Qp is the rate of plasma exchange, P is the net synthesis rate of
monitored substance, C is its concentration, and K1 is endoge-
nous clearance.
With minimal plasma volume changes this equation integrates
to yield:
1
—
— Qztn I-f (30)L'-i — rj/zj v
where Q = Qp + K1.
If only endogenous removal or clearance (K1) is operating:
/ K1t\ P1 1 / K1t\1C1(t) = C1
exp— —) + j- 1 — . (31)
The kinetic model can also be applied to examine chemo-
therapy. In this case, equation (31) can be used to view changes
in K1 and P1 relative to changes in drug administration. Clearly,
with one equation and two possible unknowns, P1 and K1, it is
necessary to have some idea as to which of the two parameters
is likely to be most affected. It is possible to measure K1
independently, for example, by collecting and separating chro-
matographically the patient's immunoglobulins, labeling the
proteins with either 1251 or a conjugated chromophore, subse-
quently reinfusing the labeled species and then examining
endogenous removal. P1 can then be estimated for the unlabeled
species. If P1 were found to vary with C1, then the model would
have to be appropriately modified. By this approach or an
analogous one, a better appreciation of how plasma exchange or
chemotherapy perturbs the immune system can be obtained.
Conclusion
Kinetic modeling applied to health care delivery, with or
without a computer, is in its infancy. It is a simple yet powerful
concept which can help rationalize and improve both diagnosis
and treatment. In essence, modeling is the application of the
logic of dynamics to therapy and it has been shown, in very
simple applications, to be very effective. The examples provid-
ed in this review—the modeling of hemoperfusion for drug
removal, precise anticoagulation, and urea kinetic modeling—
serve to point out that fairly simple mathematical representa-
tions of the body can be used to understand and improve
diagnosis and treatment. It is also conceded that modeling is not
a treatment panacea nor a substitute for thinking. In fact, it
really forces one to focus on a problem from a different
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perspective, hopefully providing new insights, as well as im-
proved delivery of therapy.
There is little doubt, with the advent of cheap and efficient
microcomputers, that individualized patient treatment and clini-
cal data-base management will become widespread. This proc-
ess will lead to more rewarding delivery, as well as receipt of
therapy.
Summary. Kinetic modeling, as the name implies, involves a
study of the dynamics or rate of change of process or system to
either gain enhanced understanding or predict an outcome. In
applying kinetics to extracorporeal treatment both goals are
encompassed. For example, in dialysis treatment the question
of mortality has been replaced by questions of morbidity and
rehabilitation. To improve the latter, it is essential to study the
kinetics of interaction between the patient and the treatment
process; mathematical models can provide both useful insights
and better patient management. The application of kinetics to
hemodialysis treatment is best exemplified by urea and heparin
modeling in these cases, the amount of dialysis is geared to the
patient's dietary protein intake, if the level is within acceptable
limits and heparin requirements are assessed by a particular
patient's sensitivity to the drug and his/her rate of elimination of
the drug. Other useful examples of the applications of kinetic
modeling in extracorporeal treatment include hemoperfusion
and therapeutic plasmapheresis.
Kinetics is not, however, a treatment panacea, or a substitute
for thinking; the real benefit of the procedure is that it forces
one to focus on a problem from a different perspective. This, in
turn, begets new disease and treatment insights as well as
improved health care delivery. The future will see a more
widespread use of kinetic analysis in a variety of other medical!
surgical procedures.
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